Company profile
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed
- CEO
- Dr. Mark J. Litton M.B.A., Ph.D.
- Headquarters
- Bothell, WA, United States
- Employees
- 26
- IPO date
- Sep 18, 2020
- Sector
- Healthcare
- Industry
- Biotechnology